Transient ischemic attack caused by cerebral ergotism
Gustavo Andrés Gaye Saavedra+3 more
doaj +1 more source
Ticagrelor or dipyridamole plus aspirin may be a promising antiplatelet therapy in patients with minor stroke or transient ischemic attack: a bayesian network meta-analysis. [PDF]
Qin S+5 more
europepmc +1 more source
Limb-shaking transient ischemic attack in internal carotid artery occlusion.
Youshi Fujita+3 more
openalex +2 more sources
Limb-Shaking Transient Ischemic Attack Induced by Middle Cerebral Artery Stenosis [PDF]
Weijian Jiang+4 more
openalex +1 more source
The H2‐Registry: overview, first results and outlook. Abstract Aims Heart failure (HF) is a highly prevalent condition affecting 1–3% of the adult population in Europe. Despite landmark improvements in HF care over the last two decades, hospitalization and mortality rates remain relatively high.
Johannes Leiner+15 more
wiley +1 more source
Physical activity modification following a Transient Ischemic Attack in individuals with diabetes. [PDF]
Mavridis A+3 more
europepmc +1 more source
Cerebral Microhemorrhages Predict New Disabling or Fatal Strokes in Patients With Acute Ischemic Stroke or Transient Ischemic Attack [PDF]
Jean-Martin Boulanger+8 more
openalex +1 more source
Abstract Aims Classifying patients as responders or non‐responders to cardiac resynchronization therapy (CRT) has been recently challenged, suggesting that preventing heart failure (HF) progression may also provide survival benefits. We assessed a novel classification based on echocardiographic left ventricular (LV) reverse remodelling and the ...
Anna Zsofia Toth+8 more
wiley +1 more source
Evaluation of systemic immune-inflammation index and systemic inflammation response index in the differentiation of acute Ischemic stroke and transient Ischemic attack. [PDF]
Yilmaz M+3 more
europepmc +1 more source
Immune Checkpoint Inhibitors and Cardiovascular Adverse Events
Abstract In the last years, we assisted to a tremendous increase in therapeutic options for the management of cancers, with immunotherapy at the forefront of this innovation. Immune checkpoint inhibitors (ICIs) have been developed to enhance the activity of the immune system against cancer cells (1) and the number of approvals for ICIs has rapidly ...
Maria Luisa De Perna+4 more
wiley +1 more source